Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03433469
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
- NCT03433469 ↗
- Active, not recruiting
- University of California, San Francisco
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03433469 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03433469 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 post on Bluesky |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Cancer; Stage IB Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Cancer; Stage IIB Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer
- Interventions
- Osimertinib; Therapeutic Conventional Surgery
- Arms
- Treatment (osimertinib) · Experimental
- Enrollment
- 27
- Primary outcomes
- Percentage of Participants With a Major Pathological Response (MPR)
- Sponsor
- University of California, San Francisco with AstraZeneca
- Start
- Jul 31, 2018
- Primary completion
- Jan 31, 2023
- Results posted
- Yes
- Registry record
- NCT03433469 · updated Mar 30, 2026
Publications
linked from the registry- Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. doi: 10.1200/JCO.24.00071. Epub 2024 Jul 19. PubMed 39028931